A new era in prostate cancer therapy: new targets and novel therapeutics.
- Published in:
- Targeted Oncology, 2008, v. 3, n. 1, p. 31, doi. 10.1007/s11523-007-0067-0
- By:
- Publication type:
- Article
Works matching IS 17762596 AND DT 2008 AND VI 3 AND IP 1
Results: 8
1
2
ErbB1–ErbB4 nuclear and cytoplasmic overexpression, ethnicity and predicted outcome in prostate cancer.
- Published in:
- Targeted Oncology, 2008, v. 3, n. 1, p. 13, doi. 10.1007/s11523-007-0069-y
- By:
- Publication type:
- Article
3
From suntan to skin cancers: molecular pathways and prevention strategies.
- Published in:
- Targeted Oncology, 2008, v. 3, n. 1, p. 41, doi. 10.1007/s11523-007-0066-1
- By:
- Publication type:
- Article
4
Biological significance of myeloperoxidase (MPO) on green tea component, (−)-epigallocatechin-3-gallate (EGCG)-induced apoptosis: its therapeutic potential for myeloid leukemia.
- Published in:
- Targeted Oncology, 2008, v. 3, n. 1, p. 45, doi. 10.1007/s11523-007-0065-2
- By:
- Publication type:
- Article
5
From the bench to the bedside: emerging new treatments in multiple myeloma.
- Published in:
- Targeted Oncology, 2008, v. 3, n. 1, p. 19, doi. 10.1007/s11523-007-0072-3
- By:
- Publication type:
- Article
6
Phase I and pharmacokinetic study of vatalanib plus capecitabine in patients with advanced cancer.
- Published in:
- Targeted Oncology, 2008, v. 3, n. 1, p. 3, doi. 10.1007/s11523-007-0070-5
- By:
- Publication type:
- Article
7
New therapies in squamous cell carcinoma of the head and neck: is the future in combined therapies?
- Published in:
- 2008
- By:
- Publication type:
- Editorial
8
Optimizing antiangiogenic strategies: combining with radiotherapy.
- Published in:
- Targeted Oncology, 2008, v. 3, n. 1, p. 51, doi. 10.1007/s11523-007-0068-z
- By:
- Publication type:
- Article